Pleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes

Henri K Parson, Meredith A Bundy, Charlotte B Dublin, Amanda L Boyd, James F Paulson, Aaron I VinikLeonard R. Strelitz Diabetes Center, Department of Internal Medicine Eastern Virginia Medical School, Norfolk, Virginia, USAAbstract: Rosuvastatin is known to reduce low-density lipoprotein (LDL)-chole...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Parson H
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	neurovascular function rosuvastatin and diabetes Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/9cbf4e31e9d74840b13e6430fc1dd6b9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9cbf4e31e9d74840b13e6430fc1dd6b9
record_format	dspace
spelling	oai:doaj.org-article:9cbf4e31e9d74840b13e6430fc1dd6b92021-12-02T02:35:03ZPleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes1178-7007https://doaj.org/article/9cbf4e31e9d74840b13e6430fc1dd6b92010-01-01T00:00:00Zhttps://www.dovepress.com/pleiotropic-effects-of-rosuvastatin-on-microvascular-function-in-type--peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Henri K Parson, Meredith A Bundy, Charlotte B Dublin, Amanda L Boyd, James F Paulson, Aaron I VinikLeonard R. Strelitz Diabetes Center, Department of Internal Medicine Eastern Virginia Medical School, Norfolk, Virginia, USAAbstract: Rosuvastatin is known to reduce low-density lipoprotein (LDL)-cholesterol and improve endothelial function. In addition to lipid-lowering, statins may exert pleiotropic (nonlipid lowering) effects on microvascular function. We compared the neurophysiological and vascular responses of dietary control and treatment with 10 mg of rosuvastatin in 16 subjects with neuropathy and established type 2 diabetes. Skin blood flow (SkBF) measurements were measured at baseline, after 18 weeks of diet, and after 18 weeks of diet and treatment with rosuvastatin in response to local warming and ischemia reperfusion. The study results show that total cholesterol (196.50 ± 8.02 to 134.88 ± 10.86 mg/dL) and LDL-cholesterol (114 ± 10.4 to 63.4 ± 8.48 mg/dL) decreased significantly after 18 weeks of rosuvastatin, but not after 18 weeks of diet. Neuropathy scores decreased from 8.34 ± 1.26 at baseline to 6.00 ± 0.90 after rosuvastatin treatment. Basal SkBF was significantly different from baseline, 6.81 ± 0.42 to 9.92 ± 0.78 after rosuvastatin treatment (P ≤ 0.001). These results indicate that rosuvastatin therapy positively changed basal SkBF and measures of neurovascular function. Although there was a profound lipid lowering, it is not clear that this mediated the increases in SkBF and decreases in neuropathy scores.Keywords: neurovascular function, rosuvastatin, diabetesParson HDove Medical Pressarticleneurovascular functionrosuvastatinand diabetesSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 3, Pp 19-26 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	neurovascular function rosuvastatin and diabetes Specialties of internal medicine RC581-951
spellingShingle	neurovascular function rosuvastatin and diabetes Specialties of internal medicine RC581-951 Parson H Pleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes
description	Henri K Parson, Meredith A Bundy, Charlotte B Dublin, Amanda L Boyd, James F Paulson, Aaron I VinikLeonard R. Strelitz Diabetes Center, Department of Internal Medicine Eastern Virginia Medical School, Norfolk, Virginia, USAAbstract: Rosuvastatin is known to reduce low-density lipoprotein (LDL)-cholesterol and improve endothelial function. In addition to lipid-lowering, statins may exert pleiotropic (nonlipid lowering) effects on microvascular function. We compared the neurophysiological and vascular responses of dietary control and treatment with 10 mg of rosuvastatin in 16 subjects with neuropathy and established type 2 diabetes. Skin blood flow (SkBF) measurements were measured at baseline, after 18 weeks of diet, and after 18 weeks of diet and treatment with rosuvastatin in response to local warming and ischemia reperfusion. The study results show that total cholesterol (196.50 ± 8.02 to 134.88 ± 10.86 mg/dL) and LDL-cholesterol (114 ± 10.4 to 63.4 ± 8.48 mg/dL) decreased significantly after 18 weeks of rosuvastatin, but not after 18 weeks of diet. Neuropathy scores decreased from 8.34 ± 1.26 at baseline to 6.00 ± 0.90 after rosuvastatin treatment. Basal SkBF was significantly different from baseline, 6.81 ± 0.42 to 9.92 ± 0.78 after rosuvastatin treatment (P ≤ 0.001). These results indicate that rosuvastatin therapy positively changed basal SkBF and measures of neurovascular function. Although there was a profound lipid lowering, it is not clear that this mediated the increases in SkBF and decreases in neuropathy scores.Keywords: neurovascular function, rosuvastatin, diabetes
format	article
author	Parson H
author_facet	Parson H
author_sort	Parson H
title	Pleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes
title_short	Pleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes
title_full	Pleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes
title_fullStr	Pleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes
title_full_unstemmed	Pleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes
title_sort	pleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/9cbf4e31e9d74840b13e6430fc1dd6b9
work_keys_str_mv	AT parsonh pleiotropiceffectsofrosuvastatinonmicrovascularfunctionintype2diabetes
_version_	1718402365555474432

Pleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes

Ejemplares similares